<DOC>
	<DOC>NCT00234546</DOC>
	<brief_summary>The aim of this clinical study is to investigate the efficacy and safety of DysportÂ® in patients with early onset of upper limb spasticity within 2-12 weeks after stroke.</brief_summary>
	<brief_title>Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity</brief_title>
	<detailed_description />
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Firstever stroke according to the World Health Organisation criteria (previous transient ischaemic attack or clinically silent infarct on CT/MRI is not counted as previous stroke) CT/MRI scan required to classify ischaemic / haemorrhagic stroke Patient recruited 212 weeks after stroke Modified Ashworth Spasticity Score 1+ or above in either elbow or wrist joint The patient has bleeding disturbances or having used coumarin derivatives The patient is currently receiving drugs affecting neuromuscular transmission Coexisting severe systemic illness which may adversely affect the functional outcome Preexisting neuromuscular junction disease or any neurogenic disorders which can interfere with spasticity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>